Literature DB >> 18753704

Anti-atherogenic actions of high-density lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I.

Fumikazu Okajima1, Koichi Sato, Takao Kimura.   

Abstract

Plasma high-density lipoprotein (HDL) is a potent anti-atherogenic factor, a critical role of which is thought to be reverse cholesterol transport through the lipoprotein-associated apolipoprotein A-I (apoA-I). HDL also carries a potent bioactive lipid mediator, sphingosine 1-phophate (S1P), which exerts diverse physiological and pathophysiological actions in a variety of biological systems, including the cardiovascular system. In addition, HDL-associated apoA-I is known to stimulate intracellular signaling pathways unrelated to transporter activity. Mounting evidence indicates that multiple antiatherogenic or anti-inflammatory actions of HDL independent of cholesterol metabolism are mediated by the lipoprotein-associated S1P through S1P receptors and by apoA-I through scavenger receptor class B type I.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753704     DOI: 10.1507/endocrj.k08e-228

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  15 in total

1.  HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.

Authors:  Yoshitaka Sekine; Kazuhiro Suzuki; Alan T Remaley
Journal:  Prostate       Date:  2010-10-26       Impact factor: 4.104

2.  Role of sphingosine 1-phosphate in anti-atherogenic actions of high-density lipoprotein.

Authors:  Koichi Sato; Fumikazu Okajima
Journal:  World J Biol Chem       Date:  2010-11-26

3.  High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism.

Authors:  Yoshitaka Sekine; Steve J Demosky; John A Stonik; Yosuke Furuya; Hidekazu Koike; Kazuhiro Suzuki; Alan T Remaley
Journal:  Mol Cancer Res       Date:  2010-07-29       Impact factor: 5.852

Review 4.  Sphingosine 1-phosphate in coagulation and inflammation.

Authors:  Hideru Obinata; Timothy Hla
Journal:  Semin Immunopathol       Date:  2011-07-31       Impact factor: 9.623

5.  S1P in HDL promotes interaction between SR-BI and S1PR1 and activates S1PR1-mediated biological functions: calcium flux and S1PR1 internalization.

Authors:  Mi-Hye Lee; Kathryn M Appleton; Hesham M El-Shewy; Mary G Sorci-Thomas; Michael J Thomas; Maria F Lopes-Virella; Louis M Luttrell; Samar M Hammad; Richard L Klein
Journal:  J Lipid Res       Date:  2016-11-23       Impact factor: 5.922

6.  Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions.

Authors:  Hideru Obinata; Sarah Gutkind; Jeremiah Stitham; Toshiaki Okuno; Takehiko Yokomizo; John Hwa; Timothy Hla
Journal:  J Lipid Res       Date:  2014-10-07       Impact factor: 5.922

7.  Negatively cooperative binding of high-density lipoprotein to the HDL receptor SR-BI.

Authors:  Thomas J F Nieland; Shangzhe Xu; Marsha Penman; Monty Krieger
Journal:  Biochemistry       Date:  2011-02-25       Impact factor: 3.162

8.  Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells.

Authors:  Takao Kimura; Hideaki Tomura; Koichi Sato; Masaaki Ito; Isao Matsuoka; Doon-Soon Im; Atsushi Kuwabara; Chihiro Mogi; Hiroshi Itoh; Hitoshi Kurose; Masami Murakami; Fumikazu Okajima
Journal:  J Biol Chem       Date:  2009-12-16       Impact factor: 5.157

9.  The effect of sphingosine-1-phosphate on bone metabolism in humans depends on its plasma/bone marrow gradient.

Authors:  B-J Kim; K-O Shin; H Kim; S H Ahn; S H Lee; C-H Seo; S-E Byun; J S Chang; J-M Koh; Y-M Lee
Journal:  J Endocrinol Invest       Date:  2015-07-29       Impact factor: 4.256

Review 10.  Export and functions of sphingosine-1-phosphate.

Authors:  Roger H Kim; Kazuaki Takabe; Sheldon Milstien; Sarah Spiegel
Journal:  Biochim Biophys Acta       Date:  2009-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.